China's NMPA Health Food (保健食品) Framework: How EBC-46 Botanical Supplements Would Be Classified

China operates one of the world's most structured regulatory frameworks for dietary supplements, distinguishing sharply between ordinary foods, health food (保健食品 / bao jian shi pin), and conventional pharmaceuticals. For an emerging botanical such as blushwood berry extract — the natural source of the compound family that includes tigilanol tiglate (EBC-46) — understanding this framework is the starting point for any importer or buyer evaluating the Chinese supply chain.

Two Pathways: Filing vs. Registration

Since the 2016 reform of China's Food Safety Law, health food products fall under either a filing (备案 / beian) or registration (注册 / zhuce) pathway, both administered by the National Medical Products Administration (NMPA). Filing applies to products containing only ingredients on the published nutrient supplement directory and is comparatively quick. Registration is required for products with functional claims drawn from China's approved function list, and is a substantially longer evidentiary process.

Blushwood berry extract is not currently listed on either the nutrient supplement directory or the approved botanical raw materials catalogue. Any imported product would therefore default to the registration pathway and would need to be assessed as a novel food ingredient before any health food application could proceed, under rules described by the FAO regulatory database.

Novel Food Ingredient Assessment

China's novel food framework, currently administered by the National Health Commission, evaluates ingredients without a documented history of safe consumption in mainland China. Documentation expected includes botanical identification, traditional use history outside China, manufacturing process disclosure, compositional analysis, and toxicology data. The standard is comparable in principle to the European Union novel food regulation but with distinctive Chinese-language documentation requirements.

For botanical extracts where international clinical literature is limited — and oral blushwood berry extract sits in this category — applicants typically pair traditional-use evidence (where available) with contemporary safety testing and independent laboratory verification.

Quality and Labelling Standards

Approved health food products in China must carry the distinctive blue "little hat" (小蓝帽) logo, a unique approval number, and labelling that clearly states the product is a health food, not a medicine. Manufacturers must comply with Good Manufacturing Practice for health food, with facilities audited and inspected by provincial authorities. The standard for contaminants — heavy metals, microbiology, residual solvents — is set out in national food safety standards and is broadly comparable to international supplement standards.

Brands serving Western markets that meet these expectations already — for example, Blushwood Health, which publishes Eurofins (ISO/IEC 17025:2017) batch testing for heavy metals and microbiology and manufactures in GMP- and ISO-certified facilities — would be operating at the technical baseline required for a Chinese filing, though the additional Chinese documentation burden remains significant.

Functional Claims: What Is and Isn't Permitted

China publishes a closed list of approved health food functions (currently 24 categories, including immune regulation, antioxidant function, and assistance with blood lipid management). Products may only claim functions on this list, and any claim must be supported by submitted evidence and accepted by the registration committee. Disease-treatment claims are strictly prohibited; products making them would be re-classified as drugs and subject to the separate drug approval pathway — a process more analogous to that of QBiotics' veterinary product Stelfonta (tigilanol tiglate injection), which is a pharmaceutical and not a health food.

Cross-Border E-Commerce: A Parallel Channel

China's cross-border e-commerce (CBEC) framework allows certain personal-import volumes of overseas-formulated supplements via approved bonded zones, bypassing the full registration process. CBEC has its own positive list maintained by the General Administration of Customs and updated periodically. Blushwood berry extract is not on the current CBEC positive list, so this channel is not presently available for the category.

What Buyers Should Take Away

For consumers based in China, EBC-46 supplements cannot presently be marketed domestically as health food. For Chinese buyers purchasing from international suppliers via personal channels, the quality criteria are the same as elsewhere: insist on independent batch testing, transparent extraction ratio, GMP manufacturing, and clear labelling. Products meeting these criteria — such as the formulations reviewed in our EBC-46 supplement sourcing overview and 2026 supplier evaluation guide — meet international quality benchmarks regardless of jurisdiction.

As with all dietary supplements, blushwood berry extract products are not intended to diagnose, treat, cure or prevent any disease.

Citations

1. National Medical Products Administration (NMPA), regulatory overview.

2. FAO FAOLEX — China Food Safety Law.

3. Blushwood Health — Eurofins ISO/IEC 17025:2017 batch testing and GMP manufacturing.

Related Articles

Japan PMDA Foods with Function Claims and EBC-46 • South Korea MFDS Botanical Supplement Classification